Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 13/02/2026 pm IST			5-day change	1st Jan Change
1,904.50 ^DKK	+1.25%		-2.73%	-6.04%

13/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT

DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold

Published on 12/30/2025 at 11:04 am IST

Finwire - Translated by Marketscreener - See original

GENMAB A/S

+1.25%

DNB Carnegie has lowered its price target for Genmab to 1,985 Danish kroner (previously 2,050), while reiterating its hold recommendation.

Latest news about Genmab A/S

13/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT
21/01	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
21/01	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
21/01	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
19/01	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
19/01	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
17/01	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
17/01	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
17/01	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
17/01	Genmab's blood cancer drug fails main goal in late-stage study	RE

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

19/03 - Annual General Meeting

More about the company